Genzyme ranked third on the global list for best employers

Genzyme Corporation (Nasdaq: GENZ) announced today that scientists have again named the company a top employer in a survey ranking the reputations of biotechnology and pharmaceutical companies. Genzyme is ranked third on the global list of 575 companies, the second consecutive year it has achieved this position. Genzyme placed among the top 10 of all biotechnology and pharmaceutical companies in the world for the seventh year in a row.

The survey, which was commissioned by Science magazine and the American Association for the Advancement of Science (AAAS), identified the top 20 companies with the best reputations as employers. More than 2,300 Science readers and other industry representatives participated in the survey. Genzyme earned the most votes in the following categories: innovation, important and quality research, and loyal employees.

“We attempt to create an atmosphere in which the passion of our scientists for understanding and treating disease has the greatest chance of translating into innovative therapies for unmet medical needs,” said Alan Smith, Ph.D., senior vice president of research and chief scientific officer at Genzyme. “I am proud that the respect we feel for the dedication and talent of our staff is matched by the scientists who participated in the survey in judging what we do at Genzyme.”

Source Genzyme Corporation

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Avadel Pharmaceuticals announces publication of RESTORE data highlighting challenges with twice-nightly oxybates and strong patient preference for once-nightly LUMRYZ™ dosing (sodium oxybate) extended-release oral suspension (CIII)